Saturday, January 19, 2008
statines, ACE remmers en Beta-blokkers
Drugs improve survival of HF patients with preserved systolic function
16 January 2008
MedWire News: Statins, angiotensin-converting enzyme (ACE) inhibitors, and beta blockers are associated with improved short- and long-term survival in elderly heart failure (HF) patients with preserved left ventricular (LV) systolic function, a US study of over 13,000 Medicare beneficiaries reveals.
"Interestingly, the mortality benefit was more profound with statin therapy than with ACE inhibitors or beta blockers," note the study authors, led by Rahman Shah from Yale University in New Haven, Connecticut, USA.
Writing in the American Journal of Cardiology, the team explains that while studies have demonstrated the benefits of these agents in HF patients with low LV ejection fraction (LVEF), data for patients with HF and preserved LVEF are limited.
The researchers studied a nationwide sample of 13,533 patients aged 65 years or older who were hospitalized with a primary discharge diagnosis of HF and preserved LVEF between 1998 and 1999, or between 2000 and 2001. They looked at how the patients' outcomes over the next 3 years related to whether or not they were prescribed statins, ACE inhibitors, or beta blockers at discharge.
After adjusting for demographic profile, clinical characteristics, treatments, physician specialty, and hospital characteristics, patients prescribed a statin at discharge had significant 31% and 27% reductions in mortality risk relative to those who did not receive statins at 1 year and 3 years of follow-up, respectively.
These benefits were apparent regardless of age, total cholesterol level, coronary artery disease status, and history of diabetes or hypertension, the authors highlight.
Similarly, patients prescribed an ACE inhibitor had better survival than those not prescribed these drugs, with a 12% reduction in mortality at 1 year, and a 7% reduction at 3 years.
Meanwhile, beta blocker therapy was associated with a nonsignificant trend toward improved survival at 1 year, at a 7% reduction in mortality compared with no beta blockers, and significantly better survival at 3 years, at an 8% reduction in mortality.
"These data provide important insights into the potential role of these agents in a large cohort of older persons with HF and preserved LVEF," Shah and co-workers conclude.
Am J Cardiol 2008; 101: 217-222
16 January 2008
MedWire News: Statins, angiotensin-converting enzyme (ACE) inhibitors, and beta blockers are associated with improved short- and long-term survival in elderly heart failure (HF) patients with preserved left ventricular (LV) systolic function, a US study of over 13,000 Medicare beneficiaries reveals.
"Interestingly, the mortality benefit was more profound with statin therapy than with ACE inhibitors or beta blockers," note the study authors, led by Rahman Shah from Yale University in New Haven, Connecticut, USA.
Writing in the American Journal of Cardiology, the team explains that while studies have demonstrated the benefits of these agents in HF patients with low LV ejection fraction (LVEF), data for patients with HF and preserved LVEF are limited.
The researchers studied a nationwide sample of 13,533 patients aged 65 years or older who were hospitalized with a primary discharge diagnosis of HF and preserved LVEF between 1998 and 1999, or between 2000 and 2001. They looked at how the patients' outcomes over the next 3 years related to whether or not they were prescribed statins, ACE inhibitors, or beta blockers at discharge.
After adjusting for demographic profile, clinical characteristics, treatments, physician specialty, and hospital characteristics, patients prescribed a statin at discharge had significant 31% and 27% reductions in mortality risk relative to those who did not receive statins at 1 year and 3 years of follow-up, respectively.
These benefits were apparent regardless of age, total cholesterol level, coronary artery disease status, and history of diabetes or hypertension, the authors highlight.
Similarly, patients prescribed an ACE inhibitor had better survival than those not prescribed these drugs, with a 12% reduction in mortality at 1 year, and a 7% reduction at 3 years.
Meanwhile, beta blocker therapy was associated with a nonsignificant trend toward improved survival at 1 year, at a 7% reduction in mortality compared with no beta blockers, and significantly better survival at 3 years, at an 8% reduction in mortality.
"These data provide important insights into the potential role of these agents in a large cohort of older persons with HF and preserved LVEF," Shah and co-workers conclude.
Am J Cardiol 2008; 101: 217-222
# posted by roodbont @ 12:41 AM 
